J&J sells off its feminine side; Manhattan Research's study on the sales rep "tablet dance"; Cepheid rolls out a consumer TB campaign; and healthcare sector job losses top out in July.
Merck came late to the iPad party, but the company has made up the distance by releasing a global template for details using the device.
Pharmas are spending far less on reprints and far more on digital promotion to physicians and other healthcare professionals, according to a healthcare media buying specialist.
HPV vaccine price cut; Merck files new allergy med with FDA; GSK pursues online transparency; Walgreens ready for greater nurse autonomy; Epocrates ranks high among docs with tablets.
Takeda's 1,800 field reps are getting a new tool, Google changes its AdWords program.
From tech shifts to talent, and from emerging markets to engaging with social media, agency execs offer their predictions for what the New Year will bring.
HBA honors Cardinal Health, BMS adds another drug to the trash heap, Spyglass says nurses don't really like iPads and Cochrane finds texting is a good way to help smokers become quitters.
Studies show that printed pieces still hold sway in the industry.
Statistics show medical professionals are migrating toward iPads. Now, one medical journal publisher says, advertisers have followed.
WebMD the Magazine is now part of the iPad app world.
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.